Review



dopaminergic neuron differentiation medium  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC dopaminergic neuron differentiation medium
    Dopaminergic Neuron Differentiation Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dopaminergic neuron differentiation medium/product/ATCC
    Average 94 stars, based on 10 article reviews
    dopaminergic neuron differentiation medium - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    94
    ATCC dopaminergic neuron differentiation medium
    Dopaminergic Neuron Differentiation Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dopaminergic neuron differentiation medium/product/ATCC
    Average 94 stars, based on 1 article reviews
    dopaminergic neuron differentiation medium - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec stemmacs trilineage differentiation kit
    Stemmacs Trilineage Differentiation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stemmacs trilineage differentiation kit/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    stemmacs trilineage differentiation kit - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    94
    Cusabio 236 cd63
    236 Cd63, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/236 cd63/product/Cusabio
    Average 94 stars, based on 1 article reviews
    236 cd63 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    96
    AMS Biotechnology skeletal muscle differentiation kit
    Skeletal Muscle Differentiation Kit, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skeletal muscle differentiation kit/product/AMS Biotechnology
    Average 96 stars, based on 1 article reviews
    skeletal muscle differentiation kit - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec stemmacs trilineage kit
    Stemmacs Trilineage Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stemmacs trilineage kit/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    stemmacs trilineage kit - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    TaKaRa osteoclast differentiation
    (A) A pictographic illustration of the workflow for this experiment, created in BioRender. Green, R. (2025) https://BioRender.com/seaeapz . Osteoclasts derived from Human PBMCs were grown on bone chips in osteoclastogenic media for 14 days with media collected at day 12 and cells were fixed and stained for TRAP at day 14. Media treatments included GALT model media (Vehicle), media control-treated GALT-conditioned basolateral media (GALT), or apical SBD111-treated GALT-conditioned basolateral media (MOI 10). Following fixation, cells were stained for TRAP and quantified using NOISe. ( B ) Representative images of TRAP+ osteoclasts grown on bone chips illustrating effects of treated media. ( C ) Example of NOISe quantification and segmentation abilities. ( D ) NOISe-based quantification of <t>osteoclast</t> number and ( E ) TRAP+ area. ( F ) CTX-1 levels (a soluble measure of resorbed bone) were measured by ELISA in media collected from the osteoclast culture 12 days post isolation. Bars indicate mean and SEM based on n = 3 for count and area measures ( D, E ). Boxplots represent median and interquartile range, with whiskers representing max and min values, of n = 4 independent experiments for bone resorption ( F ). Vehicle condition is shown to display the normal range of human PBMC-derived osteoclast resorption and differentiation measures. Significance between conditions was determined by one-way ANOVA with Tukey’s HSD and significant p values ( p < 0.05) are included presented.
    Osteoclast Differentiation, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osteoclast differentiation/product/TaKaRa
    Average 96 stars, based on 1 article reviews
    osteoclast differentiation - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec stemmacstm trilineage differentiation kit
    (A) A pictographic illustration of the workflow for this experiment, created in BioRender. Green, R. (2025) https://BioRender.com/seaeapz . Osteoclasts derived from Human PBMCs were grown on bone chips in osteoclastogenic media for 14 days with media collected at day 12 and cells were fixed and stained for TRAP at day 14. Media treatments included GALT model media (Vehicle), media control-treated GALT-conditioned basolateral media (GALT), or apical SBD111-treated GALT-conditioned basolateral media (MOI 10). Following fixation, cells were stained for TRAP and quantified using NOISe. ( B ) Representative images of TRAP+ osteoclasts grown on bone chips illustrating effects of treated media. ( C ) Example of NOISe quantification and segmentation abilities. ( D ) NOISe-based quantification of <t>osteoclast</t> number and ( E ) TRAP+ area. ( F ) CTX-1 levels (a soluble measure of resorbed bone) were measured by ELISA in media collected from the osteoclast culture 12 days post isolation. Bars indicate mean and SEM based on n = 3 for count and area measures ( D, E ). Boxplots represent median and interquartile range, with whiskers representing max and min values, of n = 4 independent experiments for bone resorption ( F ). Vehicle condition is shown to display the normal range of human PBMC-derived osteoclast resorption and differentiation measures. Significance between conditions was determined by one-way ANOVA with Tukey’s HSD and significant p values ( p < 0.05) are included presented.
    Stemmacstm Trilineage Differentiation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stemmacstm trilineage differentiation kit/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    stemmacstm trilineage differentiation kit - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    90
    STEMCELL Technologies Inc mesenculttm osteogenic differentiation kit
    (A) A pictographic illustration of the workflow for this experiment, created in BioRender. Green, R. (2025) https://BioRender.com/seaeapz . Osteoclasts derived from Human PBMCs were grown on bone chips in osteoclastogenic media for 14 days with media collected at day 12 and cells were fixed and stained for TRAP at day 14. Media treatments included GALT model media (Vehicle), media control-treated GALT-conditioned basolateral media (GALT), or apical SBD111-treated GALT-conditioned basolateral media (MOI 10). Following fixation, cells were stained for TRAP and quantified using NOISe. ( B ) Representative images of TRAP+ osteoclasts grown on bone chips illustrating effects of treated media. ( C ) Example of NOISe quantification and segmentation abilities. ( D ) NOISe-based quantification of <t>osteoclast</t> number and ( E ) TRAP+ area. ( F ) CTX-1 levels (a soluble measure of resorbed bone) were measured by ELISA in media collected from the osteoclast culture 12 days post isolation. Bars indicate mean and SEM based on n = 3 for count and area measures ( D, E ). Boxplots represent median and interquartile range, with whiskers representing max and min values, of n = 4 independent experiments for bone resorption ( F ). Vehicle condition is shown to display the normal range of human PBMC-derived osteoclast resorption and differentiation measures. Significance between conditions was determined by one-way ANOVA with Tukey’s HSD and significant p values ( p < 0.05) are included presented.
    Mesenculttm Osteogenic Differentiation Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mesenculttm osteogenic differentiation kit/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    mesenculttm osteogenic differentiation kit - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) A pictographic illustration of the workflow for this experiment, created in BioRender. Green, R. (2025) https://BioRender.com/seaeapz . Osteoclasts derived from Human PBMCs were grown on bone chips in osteoclastogenic media for 14 days with media collected at day 12 and cells were fixed and stained for TRAP at day 14. Media treatments included GALT model media (Vehicle), media control-treated GALT-conditioned basolateral media (GALT), or apical SBD111-treated GALT-conditioned basolateral media (MOI 10). Following fixation, cells were stained for TRAP and quantified using NOISe. ( B ) Representative images of TRAP+ osteoclasts grown on bone chips illustrating effects of treated media. ( C ) Example of NOISe quantification and segmentation abilities. ( D ) NOISe-based quantification of osteoclast number and ( E ) TRAP+ area. ( F ) CTX-1 levels (a soluble measure of resorbed bone) were measured by ELISA in media collected from the osteoclast culture 12 days post isolation. Bars indicate mean and SEM based on n = 3 for count and area measures ( D, E ). Boxplots represent median and interquartile range, with whiskers representing max and min values, of n = 4 independent experiments for bone resorption ( F ). Vehicle condition is shown to display the normal range of human PBMC-derived osteoclast resorption and differentiation measures. Significance between conditions was determined by one-way ANOVA with Tukey’s HSD and significant p values ( p < 0.05) are included presented.

    Journal: Journal of functional foods

    Article Title: A synbiotic medical food improves gut barrier function, reduces immune responses, and inhibits osteoclast activity in models of postmenopausal bone loss aligned with clinical outcomes

    doi: 10.1016/j.jff.2025.107114

    Figure Lengend Snippet: (A) A pictographic illustration of the workflow for this experiment, created in BioRender. Green, R. (2025) https://BioRender.com/seaeapz . Osteoclasts derived from Human PBMCs were grown on bone chips in osteoclastogenic media for 14 days with media collected at day 12 and cells were fixed and stained for TRAP at day 14. Media treatments included GALT model media (Vehicle), media control-treated GALT-conditioned basolateral media (GALT), or apical SBD111-treated GALT-conditioned basolateral media (MOI 10). Following fixation, cells were stained for TRAP and quantified using NOISe. ( B ) Representative images of TRAP+ osteoclasts grown on bone chips illustrating effects of treated media. ( C ) Example of NOISe quantification and segmentation abilities. ( D ) NOISe-based quantification of osteoclast number and ( E ) TRAP+ area. ( F ) CTX-1 levels (a soluble measure of resorbed bone) were measured by ELISA in media collected from the osteoclast culture 12 days post isolation. Bars indicate mean and SEM based on n = 3 for count and area measures ( D, E ). Boxplots represent median and interquartile range, with whiskers representing max and min values, of n = 4 independent experiments for bone resorption ( F ). Vehicle condition is shown to display the normal range of human PBMC-derived osteoclast resorption and differentiation measures. Significance between conditions was determined by one-way ANOVA with Tukey’s HSD and significant p values ( p < 0.05) are included presented.

    Article Snippet: Cells were analyzed for tartrate-resistant acid phosphatase (TRAP) activity to quantify osteoclast differentiation as per manufacturer’s instructions (CAT# MK301, Takara; San Jose, CA).

    Techniques: Derivative Assay, Staining, Control, Enzyme-linked Immunosorbent Assay, Isolation

    Impaired intestinal barrier integrity, as occurs during aging, obesity, and the menopause transition permits translocation of inflammatory microbial components into intestinal tissues. This activates the epithelium and local immune cells which further compromise barrier integrity, allowing translocation of additional inflammatory components. This cycle promotes systemic inflammation and promotes osteoclastogenesis and bone resorption through the migration of osteoclast-activating inflammatory immune cells and diffusion of osteoclast-modulating compounds to bone. SBD111 disrupts this cycle by enhancing intestinal barrier integrity and, in the case of disrupted barriers, by reducing inflammatory mediator secretion (T cell polarizing and neutrophil chemoattractant) by inflamed immune cells. Furthermore, SBD111 has shown the potential to produce an anti-osteoclastogenic environment through interactions with intestinal epithelial cells and underlying immune cells. Together these mechanisms may contribute to the bone-protective effects of SBD111 observed in groups of postmenopausal women. Image created in https://BioRender.com . Green, R. (2025) https://BioRender.com/sty1qzs .

    Journal: Journal of functional foods

    Article Title: A synbiotic medical food improves gut barrier function, reduces immune responses, and inhibits osteoclast activity in models of postmenopausal bone loss aligned with clinical outcomes

    doi: 10.1016/j.jff.2025.107114

    Figure Lengend Snippet: Impaired intestinal barrier integrity, as occurs during aging, obesity, and the menopause transition permits translocation of inflammatory microbial components into intestinal tissues. This activates the epithelium and local immune cells which further compromise barrier integrity, allowing translocation of additional inflammatory components. This cycle promotes systemic inflammation and promotes osteoclastogenesis and bone resorption through the migration of osteoclast-activating inflammatory immune cells and diffusion of osteoclast-modulating compounds to bone. SBD111 disrupts this cycle by enhancing intestinal barrier integrity and, in the case of disrupted barriers, by reducing inflammatory mediator secretion (T cell polarizing and neutrophil chemoattractant) by inflamed immune cells. Furthermore, SBD111 has shown the potential to produce an anti-osteoclastogenic environment through interactions with intestinal epithelial cells and underlying immune cells. Together these mechanisms may contribute to the bone-protective effects of SBD111 observed in groups of postmenopausal women. Image created in https://BioRender.com . Green, R. (2025) https://BioRender.com/sty1qzs .

    Article Snippet: Cells were analyzed for tartrate-resistant acid phosphatase (TRAP) activity to quantify osteoclast differentiation as per manufacturer’s instructions (CAT# MK301, Takara; San Jose, CA).

    Techniques: Translocation Assay, Migration, Diffusion-based Assay